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LSD1 controls metastasis of androgen-independent prostate
cancer cells through PXN and LPAR6
A Ketscher1,2, CA Jilg1, D Willmann1, B Hummel1, A Imhof3, V Rüsseler1, S Hölz1,2, E Metzger1, JM Müller1 and R Schüle1,4,5
Lysine-specific demethylase 1 (LSD1) was shown to control gene expression and cell proliferation of androgen-dependent prostate
cancer (PCa) cells, whereas the role of LSD1 in androgen-independent metastatic prostate cancer remains elusive. Here, we show
that depletion of LSD1 leads to increased migration and invasion of androgen-independent PCa cells. Transcriptome and cistrome
analyses reveal that LSD1 regulates expression of lysophosphatidic acid receptor 6 (LPAR6) and cytoskeletal genes including the focal
adhesion adaptor protein paxillin (PXN). Enhanced LPAR6 signalling upon LSD1 depletion promotes migration with concomitant
phosphorylation of PXN. In mice LPAR6 overexpression enhances, whereas knockdown of LPAR6 abolishes metastasis of
androgen-independent PCa cells. Taken together, we uncover a novel mechanism of how LSD1 controls metastasis and identify
LPAR6 as a promising therapeutic target to treat metastatic prostate cancer.
Oncogenesis (2014) 3, e120; doi:10.1038/oncsis.2014.34; published online 6 October 2014
INTRODUCTION
Prostate cancer (PCa) is the second leading cause of cancer deaths
in men worldwide.1 In early clinical stages, PCa is confined to the
prostate and can be cured by surgery and/or radiotherapy.
However, in 20–53% of the cases relapse occurs within the first
5 years.2 A large proportion of these patients initially responds to
hormone ablation therapy, but develops androgen-independent
PCa that finally metastasizes locally or distantly. Currently, there
are no therapies for these patients that prevent metastasis.
Formation of metastases requires tumour cell migration and
invasion. Migration is a tightly regulated process involving cell
polarisation, site-specific extracellular signalling, cell protrusion, as
well as the coordinated attachment to and detachment from the
extracellular matrix.3 The latter is mainly mediated by focal
adhesions (FAs), large protein complexes primarily located at the
leading edge of migrating cells. During cell protrusion, FA
turnover enables cells to reattach at new positions. FAs are built
of proteins including paxillin (PXN), talin 1 (TLN1), zyxin (ZYX) and
the regulatory subunit 2 beta of phosphoinositide-3-kinase
(PIK3R2). In response to extracellular signals such as lysopho-
sphatidic acid (LPA), PXN is phosphorylated at tyrosine 118 (Y118)
by a complex consisting of FA-Kinase (FAK) and Src.4 Previous
studies showed that overexpression of PXN, TLN1, ZYX or PIK3R2
increases cell migration and/or metastasis in various cancer types
including PCa.5–8
LPA binds to G protein-coupled transmembrane receptors that
are divided in two subgroups, the endothelial differentiation gene
family (LPAR1-3) and the purinergic receptor-related family
(LPAR4-6). Consequences on LPA signalling are diverse and only
partially understood, as distinct pathways are activated depending
on cell and receptor type.9,10
In addition to regulation of FAs by signalling events, expression
of genes encoding FA constituents is transcriptionally controlled.
In general, gene regulation requires cooperation of transcription
factors and cofactors including histone modifying enzymes such
as lysine-specific demethylase 1 (LSD1 or KDM1A). LSD1 is an
amine oxidase that specifically demethylates H3K4me2/me111 or
H3K9me2/me1,12 thereby affecting target gene transcription. To
date, there are no data describing a role for LSD1 in the regulation
of focal adhesion-associated proteins in PCa. Altered LSD1 levels
were correlated with different types of cancer.12,13 In PCa cells
LSD1 promotes transcription in cooperation with the androgen
receptor and is required for proliferation in an androgen-
dependent manner.12 In breast cancer, LSD1 was reported to
control the expression of epithelial–mesenchymal transition-
related genes as part of the NuRD complex.14 It is not known
whether a similar mechanism accounts for LSD1-controlled
metastases formation in PCa.
Here, we show that LSD1 regulates a LPAR6-FA signalling
network. LSD1 directly controls transcription of numerous focal
adhesion and cytoskeleton-associated genes. Depletion of LSD1
activates LPA signalling by upregulation of LPAR6 along with
phosphorylation of PXN resulting in increased migration of
androgen-independent PCa cells. Furthermore, in mice LPAR6
depletion dramatically impairs the formation of metastases.
Taken together, we describe a novel mechanism controlling
the metastatic behaviour of PCa cells and identify LPAR6
as a promising target to prevent metastasis of androgen-
independent PCa.
RESULTS
LSD1 controls migration and invasion of androgen-independent
PCa cells
To investigate a potential role of LSD1 in androgen-independent
PCa, we first tested the effect of RNAi-mediated knockdown of
LSD1 on the androgen receptor-negative cell lines PC-3M-luc and
DU145. We monitored migration, invasion and proliferation in
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real-time by measuring cell-mediated impedance on a microelec-
trode array, which is displayed by the cell index. Migration and
invasion of both cell lines was strongly increased upon knock-
down of LSD1 compared to cells treated with unrelated control
siRNA (Figures 1a and c). Vice versa, we observed impaired
migration when LSD1 was overexpressed in PC-3M-luc cells using
a lentivirus-driven construct (Figures 1d and e). In comparison,
proliferation was not influenced by knockdown of LSD1
(Supplementary Figures S1a and b). Overexpression of LSD1 only
marginally influenced proliferation (Supplementary Figure S1c).
Thus, LSD1 controls the migratory and invasive behaviour of
androgen-independent PCa cells.
LSD1 directly regulates transcription of cytoskeleton-associated
genes
To identify genes that mediate the effect of LSD1 on PCa cell
migration and invasion, we performed transcriptome analysis. RNA
from PC-3M-luc cells treated with either siRNA against LSD1 or
unrelated control was isolated and subjected to massive parallel
sequencing (RNA-sequencing). Bioinformatic analyses showed
that 1355 genes were differentially regulated upon knockdown
of LSD1 (Figure 2a). DAVID gene ontology analysis revealed that
knockdown of LSD1 in PC-3M-luc cells affects genes that are
linked to the proteasome complex, to centromere and kineto-
chore of chromosomes and to the basolateral plasma membrane.
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Figure 1. LSD1 controls migration and invasion of androgen-independent prostate cancer cell lines. Migration (a) and invasion (b) assays of
PC-3M-luc and DU145 cells treated with siRNA against LSD1 (siLSD1) or unrelated control siRNA (siCtrl). (d) Migration assay of PC-3M-luc cells
overexpressing LSD1. PC-3M-luc cells were infected with either control- (GFP) or LSD1-expressing lentivirus (LSD1). (a, b, d) Cell indices and
relative velocities are shown. (c, e) Levels of LSD1 were analysed by western blots decorated with the indicated antibodies. β-Actin was used as
loading control. n⩾ 3. Error bars represent ± s.d. or +s.d. **P⩽ 0.01, ***P⩽ 0.001.
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Figure 2. LSD1 directly regulates the expression of cytoskeleton-associated genes. (a) MA-Plot representing the differentially regulated genes
(red dots) in PC-3M-luc cells upon knockdown of LSD1. (b) Pie chart displaying genomic distribution of LSD1 peaks in PC-3M-luc cells
determined by ChIP-sequencing analysis. (c) Venn diagram, showing the intersection between differentially regulated genes upon
knockdown of LSD1 and genes with LSD1 peaks at the promoter. (d) Localisation of LSD1 peaks (ChIP-sequencing) and read coverage
(RNA-sequencing) at PXN, TLN1, ZYX and PIK3R2. FC: Fold Change. (e) Migration assay of PC-3M-luc cells treated with siRNA against PXN or
control siRNA. Cell index and relative velocitiy are shown. (f) mRNA levels of PXN were analysed by qRT-PCR. n⩾ 3. Error bars represent± s.d. or
+s.d. ***P⩽ 0.001.
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Figure 3. LPAR6 mediates LSD1-controlled migration. (a) Levels of PXN and PXN Y118ph. (b) Migration assay of PC-3M-luc cells treated with
LPA or Ethanol (EtOH). (d) mRNA levels of LPAR6 were analysed by qRT-PCR. (e) Migration assay of PC-3M-luc cells treated with LPA or EtOH
and transfected with siRNA against LPAR6 or an unrelated control siRNA. (g) Migration assay of PC-3M-luc cells treated with siRNA either
against LSD1, LPAR6 or both. (h) mRNA levels of LSD1 and LPAR6 were analysed by qRT-PCR. (i) Migration assay of PC-3M-luc cells
overexpressing LPAR6. (b, e, g, i) Cell indices and relative velocities are shown. (a, c, f, k) Levels of LSD1, PXN, and PXN Y118ph were analysed
by western blots decorated with the indicated antibodies. β-Actin was used as loading control. n⩾ 3. Error bars represent± s.d. or +s.d.
*P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001.
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Interestingly, 148 (10.9%) differentially regulated genes were part
of the cytoskeleton-associated gene cluster, potentially account-
ing for the migratory phenotype (Supplementary Figure S2a).
To determine which of the cytoskeleton-associated genes are
direct LSD1 targets, we conducted chromatin immunoprecipita-
tion assay with LSD1 antibody in PC-3M-luc cells followed
by massive parallel sequencing (ChIP-sequencing). 20110
high-confidence LSD1 peaks were identified, with 51.34% located
at the promoter (±2500 bp around the transcription start site) of
9825 genes (Figure 2b). Intersection of LSD1 transcriptome and
cistrome revealed 1000 differentially regulated genes with LSD1
promoter occupancy (Figure 2c). The intersection comprised 110
of the 148 cytoskeleton-associated genes. Of these 110 genes 66
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Figure 3. Continued.
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The reorganisation of the cytoskeleton is required for efficient cell
migration.15 Thus, the deregulation of contributing proteins such
as FA components can lead to aberrant cell migration. Interest-
ingly, FA components such as PXN, TLN1, ZYX and PIK3R2 were
upregulated upon knockdown of LSD1, which was confirmed by
quantitative reverse transcription-PCR and western blot (Figure 2d,
Supplementary Figures S2b and c). Although other differentially
regulated genes could also contribute to the migratory phenotype
upon knockdown of LSD1, we focused on focal adhesion
components to track LSD-controlled migration. These data
indicate that LSD1 directly regulates cytoskeleton-associated
genes, thereby accounting for the migratory behaviour of
androgen-independent PCa cells.
To provide further evidence, that these genes are mediators of
LSD1-controlled cell migration, we treated PC-3M-luc cells with
siRNA against these FA constituents. Knockdown of PXN, TLN1,
ZYX or PIK3R2 severely impaired migration of PC-3M-luc cells
(Figures 2e and f, Supplementary Figures S2d and e). In
accordance with our data, upregulation of PXN, TLN1, ZYX and
PIK3R2 was previously correlated with enhanced cell motility in
different types of cancer.5–8 In summary, as exemplified by key
components of FAs, we demonstrate that enhanced cell migration
upon LSD1 knockdown is mediated through direct regulation of
cytoskeleton-associated genes.
LPAR6 signalling induces phosphorylation of PXN after LSD1
knockdown
Next, we investigated the influence of LSD1 knockdown on FA
signalling. Previous studies showed that phosphorylation of PXN
at Y118 (PXN Y118ph) is necessary for disassembly of FAs.16
Western blot analysis of PC-3M-luc cell lysate upon knockdown of
LSD1 revealed increased levels of PXN and PXN Y118ph
(Figure 3a). Phosphorylation of PXN occurs upon mechanical
force, integrin clustering or activation of growth factor receptors
by their ligands.17 Furthermore, phosphorylation of PXN is
detected upon activation of LPA signalling in PC-3 cells.4,18–20
Therefore, we investigated the impact of LPA on migration of
androgen-independent PCa cells. Treatment of serum-starved
PC-3M-luc cells with LPA resulted in increased PXN Y118ph levels
and migration (Figures 3b and c). LPA signals through binding to
the LPAR family members LPAR1-6.10 Our RNA-sequencing data
showed that LPAR1, 2, 3 and 6 were expressed in PC-3M-luc cells.
From these receptors only LPAR6 was differentially regulated
upon knockdown of LSD1 (Supplementary Figures S3a and b).
However, LSD1 depletion did not influence expression of the RB1
gene, which is transcribed from the opposite DNA strand of the
LPAR6 locus. ChIP-sequencing analysis showed that LPAR6 is not a
direct target of LSD1. We confirmed upregulation of LPAR6 by
quantitative reverse transcription-PCR (Figure 3d) owing to the
low quality of commercially available antibodies against LPAR6.
These data suggest that LPAR6 is a major mediator of LPA
signalling in androgen-independent PCa cells. In favour of this
idea, knockdown of LPAR6 decreased migration of PC-3M-luc cells
(Figure 3e). Furthermore, after LPAR6 knockdown, LPA no longer
stimulated migration of PC-3M-luc cells (Figure 3e) and PXN
Y118ph was reduced (Figure 3f).
To provide further evidence that increased migration and
elevated levels of PXN Y118ph upon knockdown of LSD1 are
dependent on LPAR6, we treated PC-3M-luc cells with siRNA
against LSD1 or LPAR6, either alone or in combination. Indeed,
increased migration upon knockdown of LSD1 was not observed



























































































Figure 4. LPAR6 controls migration and metastasis. Number of metastases (a) and tumour volume (b) in an orthotopic tumour model of the
mouse prostate were analysed. PC-3M-luc cells overexpressing LPAR6 (LPAR6) or control cells (Ctrl) were injected. (c) Macroscopic view
of tumours and lymph node metastases. n= 10 mice. Error bars represent+s.e.m. (d) Decreased overall metastases in mice injected with
PC-3M-luc cells after LPAR6 knockdown into the lateral tail vein. (e) Bioluminescent images taken after 28 days show metastases of PC-3M-luc
cells transfected with siRNA against LPAR6 (siLPAR6; n= 12) or unrelated control siRNA (siCtrl; n= 17). Statistics were done using Fisher’s exact
test. **P⩽ 0.01.
LSD1 controls androgen-independent PCa cells
A Ketscher et al
6
Oncogenesis (2014), 1 – 9 © 2014 Macmillan Publishers Limited
results were obtained in DU145 cells (Supplementary Figures S3c
and d).
Next, we investigated the effect of elevated LPAR6 levels on
migration of androgen-independent PCa cells. Overexpression of
LPAR6 increased migration of PC-3M-luc cells (Figure 3i) and
phosphorylation of PXN Y118ph (Figure 3j). Elevated mRNA
expression of LPAR6 upon induction with doxycyline was confirmed
by quantitative reverse transcription-PCR (Figure 3k). To demon-
strate that the LPAR6-mediated increase in migration requires
activation of FAs, we knocked down PXN in PC-3M-luc cells
overexpressing LPAR6. Whereas overexpression of LPAR6 led to
elevated migration of PC-3M-luc cells, simultaneous depletion of
PXN completely abrogated the observed phenotype
(Supplementary Figures S3e and f). Together, these results show
that LPAR6 and its downstream effector PXN are upregulated upon
knockdown of LSD1, thereby enhancing migration. Furthermore, our
data demonstrate that LSD1-controlled migration of androgen-
independent PCa cells in response to LPA is mediated by LPAR6.
LPAR6 controls metastasis of androgen-independent PCa cells
Our in vitro data suggest that metastasis of androgen-
independent PCa depends on LPAR6. To address this issue
in vivo, we used an orthotopic prostate tumour model. PC-3M-luc
cells stably overexpressing LPAR6 were injected into the dorsal
lobe of the prostate of immunodeficient mice. Five weeks after
injection, tumour size and number of lymph node metastases
were analysed. Importantly, elevated levels of LPAR6 led to a
significantly increased number of lymph node metastases
compared to the control group (Figures 4a and c). In comparison,
tumour volumes were not significantly affected (Figures 4b and c).
Tumours as well as lymph node metastases were verified by
histological staining (Supplementary Figure S4a). To further
support the role of LPAR6 in metastasis, we used a second
in vivo metastasis model, in which PCa cells extravasate from the
blood vessel system to form distant metastases. LPAR6-
overexpressing PC-3M-luc cells were injected into the lateral tail
vein of immunodeficient mice and metastases formation was
monitored by bioluminescence over 5 weeks and verified by
histological staining. LPAR6 overexpression led to a dramatically
increased number of metastases (Supplementary Figures S4b–e).
Together, the results of both models clearly show that LPAR6
controls metastasis of androgen-independent PCa cells.
To evaluate whether LPAR6 may serve as therapeutic target for
the treatment of metastatic PCa, we monitored metastases
formation upon knockdown of LPAR6 in vivo. Therefore, we
injected PC-3M-luc cells transfected with siRNA against LPAR6
or an unrelated control siRNA into the lateral tail vein of
immunodeficient mice (Supplementary Figure S4f). To ensure
the stability of LPAR6 depletion we monitored mRNA levels over
8 days post transfection (Supplementary Figure S4g). Compared to
control mice, the number of metastases was significantly lower in
mice injected with LPAR6-depleted cells (Figures 4d and e and
Supplementary Figure S4h) demonstrating that LPAR6 is crucial for
metastasis of PC-3M-luc cells. Taken together, our data imply that
inhibition of LPAR6 signalling is a novel and promising strategy to
prevent metastasis of androgen-independent PCa.
DISCUSSION
In the present study, we uncovered a novel mechanism for
LSD1-controlled migration of androgen-independent PCa cells
and identified LPAR6 as a promising target for PCa therapy.
Transcriptome and cistrome data sets provided in this manuscript
for androgen-independent PCa cells reveal that LSD1 is a direct
regulator of genes of the LPAR6-FA signalling network such as
PXN, TLN1, ZYX and PIK3R2. This mechanism of migration control
is different from the one previously observed in breast cancer
cells, where LSD1 was reported to interact with the NuRD-complex
and to regulate epithelial–mesenchymal transition-related genes
such as TGFB1, LMNB2, IGF1R, EGFR, CCND2, ADK, PSEN1, RHOA,
FGF21 and APAF1.14 In contrast, we neither observe interaction of
LSD1 with NuRD components nor regulation of these epithelial-
–mesenchymal transition-related genes in PC-3M-luc cells upon
knockdown of LSD1. Thus, LSD1 appears to control cancer cell
migration by different mechanisms in distinct types of cancer.
The role of LSD1 in PCa that is described here differs from that
in androgen-dependent PCa cells. There, LSD1 cooperates with
the androgen receptor to control androgen-dependent gene
expression and proliferation. In contrast, we could not observe
severe effects of LSD1 knockdown or overexpression on prolifera-
tion of PC-3M-luc and DU145 cells. It will be interesting to evaluate
the diverse roles of LSD1 in PCa that is either androgen receptor-
dependent or -independent.
LPAR6 was previously shown to be highly expressed in tumour
tissue and metastases of human hepatocellular carcinoma com-
pared to normal liver,21 but the function of LPAR6 was not
investigated. Our data show that overexpression of LPAR6 leads to
increased migration and metastasis of PC-3M-luc and DU145 cells.
In comparison, Liu et al. observed that transgenic mice expressing
LPAR1-3, members of the endothelial differentiation gene family,
under the control of the mouse mammary tumour virus-promoter
developed mammary tumours and metastases.22 Importantly, we
demonstrate that LPAR6 depletion dramatically decreases the
metastatic potential of androgen-independent PCa cells in mice.
Our findings uncover LPAR6 as the first member of the purinergic
receptor-related family as a promising target for the treatment of
androgen-independent PCa. Our correlation of LPAR6 expression
with metastasis suggests that LPAR6 antagonizing compounds
might be of therapeutic value to prevent metastasis. Based on
treatment with LPA antagonists, previous studies implicated LPAR1
in migration of androgen-independent PCa cells.23 However, in
these studies observations were neither verified by knockdown of
LPAR1 nor the role of LPAR6 was taken into account. Furthermore,
the authors only tested the impact of LPA antagonists directed
against members of the endothelial differentiation gene family on
migration. In comparison, LPAR6 belongs to the purinergic
receptor-related gene family, and the effects of current, low-
specificity, LPAR inhibitors on all family members have only partially
been documented. Further evaluation of the therapeutic potential
of the individual LPAR family members requires the development of
novel inhibitors with high affinity and specificity. In addition, the
development of specific and high quality antibodies against LPAR6
will provide insights into expression pattern of LPAR6 in different
stages of PCa. Taken together, our analyses demonstrate that LSD1
is as a key regulator of the LPAR6-FA signalling network and identify




Expression plasmids for LSD1 and LPAR6 were generated by LRII
recombination according to the supplier (Gateway, Invitrogen, Carlsbad,
CA, USA) using entry clones (GeneCopoeia, Rockville, MD, USA; GC-I0048-CF;
accession number NM_001162498; pENTR-D-TOPO-LSD1, Schüle Laboratory,
Freiburg, Germany) and either a puromycin-selectable and doxycycline-
inducible pRTS plasmid55 (modified to contain a Gateway cassette, V5 and
His-tag epitope) or FU-GFP vector (kindly provided by Owen Witte, UCLA,
Los Angeles, CA, USA). Vectors without insert were used as control.
Cell culture and transfection
PC-3M-luc cells and DU145 cells were cultured in EMEM (Lonza, Basel,
Switzerland, 12–125) supplemented with 10% FCS, 1% L-glutamine (Lonza,
BE17-605E) and 1% penicillin-streptomycin (Lonza, DE17-602E). RNAi
knockdown was performed using Dharmafect 2 (Thermo Scientific,
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Waltham, MA, USA, T-2002-01) in PC-3M cells and Dharmafect 4 (Thermo
Scientific, T-2004-01) in DU145 cells using 25 nM siRNA according to
the manufacturer’s instruction. For knockdown of LSD1 the following
siRNAs were used: siCtrl: 5′-AACGTACGCGGAATACTTCGA-3′ and siLSD1
5′-acacaaggaaag cuagaagaa-3′. For others siCtrl 5′-GAAAGTCCTAGAT
CCACACGCAAAT-3′, siLPAR6 5′-UCAGCAUGGUGUUUGUGCUUGGGUU-3′,
siPXN 5′-CATACCCAACTGGAAACCACACATA-3′, siTLN1 5′-CATTGTACTTGAT
ACGGCCAGTGAT-3′, siZYX 5′-CAGGGAGAAGGTGAGCAGTATTGAT-3′ and
siPIK3R2 5′-CCCTCAGGAAAGGCGGGAACAATA-3′. Dharmafect Duo
(Thermo Scientific, T-2010-01) was used for plasmid transfection as
described in the manual. Puromycin (Sigma, St Louis, MO, USA, P8733,
5 μg/ml) was administered to cells 24 h post transfection. 293T cells were
cultured in DMEM supplemented with 10% FCS, 1% L-glutamine and 1%
penicillin-streptomycin. Viral production was performed as described.12
PC-3M cells were infected with FU-GFP or FU-GFP-LSD1 and subjected to
migration assay 24 h post transduction.
Western blot analysis and Immunoprecipitation
Experiments were performed as described.12 Antibodies against the
following proteins were used for western blots: LSD1 (Schüle Laboratory,
3544), β-Actin (Sigma, A1978), PXN (Cell Signaling, Danvers, MA, USA,
2542), PXN Y118ph (Cell Signaling, 2541), TLN1 (AbD Serotec, Kidlington,
UK, MCA4770), ZYX (Abcam, Cambridge, UK, ab71842), PIK3R2 (Abcam,
ab28356). Western blots for phPXN (Y118) were performed 90min post
LPA induction (Figures 3b and f), 72 h after treatment with siRNA against
LSD1 (Figure 3a) or 24 h post transfection with LPAR6 overexpressing
construct (Figure 3j).
Cell proliferation, migration and invasion assays
Prior to the experiment PC-3M-luc cells were treated for 24 h with siRNA or
for 48 h with doxycycline (2 μg/ml), respectively. LPA (Cayman, Ann Arbor,
MI, USA, 10010093) was added immediately before starting the assay to
overnight serum-starved cells at a concentration of 10 μM and after serum
starvation overnight. Proliferation, cell migration and invasion were
monitored using the xCelligence system (Roche, Basel, Switzerland) that
measures electrode impedance upon cell attachment to the surface of
proliferation (E-plate) or migration (CIM-plate) chambers. For invasion,
transwell chamber filters were coated with matrigel (BD Biosciences,
Franklin Lakes, NJ, USA, 354230) diluted 1:40 in EMEM medium. For
proliferation 5 × 103 PC-3M cells and 1× 104 DU145 cells were seeded into
E-plate 16. For migration and invasion PC-3M cells were seeded at 5 × 104
and DU145 cells at 1 × 104 into the transwell containing 0.5% FCS EMEM in
the upper chamber and 10% FCS EMEM in the lower chamber. Cell indices
display electrode impedance and were automatically recorded every
15min by the xCelligence system software (Roche). Relative velocities
represent the change of the cell index over time.
RNA extraction and semiquantitative reverse transcription-PCR
RNA isolation and quantitative PCR after reverse transcription were
performed as described.12 For normalisation of expression in PC-3M-luc
and DU145 cells ACTB, HPRT1 and POLR2A were used and data were
related to negative control cells treated with control siRNA, empty vector
or empty virus. Experiments were repeated in triplicate at least three times.
Primers are shown in Supplementary Table I.
RNA sequencing
RNA samples were sequenced by the standard Illumina protocol to create
raw sequence files (.fastq files). We aligned these reads to the hg19 build of
the human genome using TopHat version 2.24 The aligned reads were
counted with the Homer software (analyzeRNA) and DEG’s were identified
using EdgeR25 and DESeq version 1.8.3.26 Only differentially regulated
genes with a P-value ⩽ 10− 5 were included in our analysis.
ChIP sequencing
Chromatin immunoprecipitation experiments were performed using the
antibody against LSD1 (Abcam, ab17721, lot GR 79477-1) on protein
A-Sepharose 4B (GE Healthcare, Chalfont St Giles, UK) essentially as
described.27 Libraries were prepared from immunoprecipitated DNA
according to standard methods. ChIP-Seq libraries were sequenced using
a HiSeq 2000 (Illumina, San Diego, CA, USA) and mapped to the hg19
reference genome using Bowtie 0.12.7.28 Data were further analyzed using
the peak finding algorithm MACS 1.429 using input as control. All peaks
with FDR bigger than 1% were excluded from further analysis. The
uniquely mapped reads were used to generate the genome-wide intensity
profiles, which were visualized using the IGV genome browser.30 HOMER31
was used to annotate peaks, calculate overlaps between different peak
files and for motif searches. The genomic features (promoter (±2500 bp
from transcription start site), exon, intron, 3′ UTR and intergenic regions)
were defined and calculated using Refseq and HOMER, respectively. To
draw the average gene profile CEAS was used.32 Genes annotated by
HOMER were further used for a DAVID analysis.33
In vivo metastasis assay
All mice were housed in the pathogen-free barrier facility of the University
Medical Center Freiburg in accordance with institutional guidelines and
approved by the regional board. Seven to eight-weeks-old male C.B-17.Cg-
Prkdcscid Lystbg/Crl-mice (Charles River, Wilmington, MA, USA) were used for
in vivo metastasis assays. In all, 1 × 106 PC-3M-luc cells were resuspended in
100 μl PBS or 20 μl matrigel and injected either into the lateral tail vein or
the dorsal lobe of the mouse prostate. For bioluminescent imaging mice
were anesthetized with isofluorane (Forene, Abbott GmbH, Chicago, IL, USA)
and 150 μg/g D-Luciferin (Caliper Life Science, Hopkinton, MA, USA, 119222)
was injected intraperitoneal. Two minutes after injection bioluminescence
was imaged for 30 s to 5min at day 7, 14, 21 and 28 of the experiment. At
day 28 mice were sacrificed and organs with luminescent signals were
collected for HE staining. For the orthotopic metastasis model primary
tumors and axillary lymph nodes were dissected after 28 days.
Statistical analysis
If not otherwise stated, significance was calculated using an unpaired t-test
and data were shown as mean± s.d. or +s.d.
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